康臣药业(01681.HK)拟于公开市场回购最多4500万股股份
格隆汇9月6日丨康臣药业(01681.HK)公布,公司决定透过行使回购公司股份的一般授权执行股份回购计划。公司将于公开市场回购其股份。
公告显示,可予回购股份总数最多4500万股股份,占于2019年5月31日公司已发行股份总数约5.16%。
公司表示,公司目前的股价低于其内在价值及投资者所认知的价值,亦为公司回购股份提供良机,股份回购计划反映董事会对公司目前业务发展和前景有信心。
再者,公司相信积极管理资本结构及执行股份回购计划将可令公司的资本结构更臻完善,并可提高股份的每股盈利及整体股东回报。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.